NUWE
Nuwellis, Inc.NASDAQHealthcareAs of 2026-04-07
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.67
P/S
0.12
EV/EBITDA
-0.03
DCF Value
$-0.62
FCF Yield
-1107.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
62.0%
Operating Margin
-134.3%
Net Margin
-211.9%
ROE
-6046.6%
ROA
-286.4%
ROIC
-331.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.4M | $-2.4M | $-1.50 |
| FY 2025 | $8.3M | $-17.5M | $-25.39 |
| Q3 2025 | $2.2M | $468.0K | $0.56 |
| Q2 2025 | $1.7M | $-12.6M | $-60.99 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.08
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.